KR100949482B1 - Phamaceutical composition of diabetes mellitus or hypertension using extract of taxus cuspidata and mulberry tree, and mamufacturing method thereof - Google Patents
Phamaceutical composition of diabetes mellitus or hypertension using extract of taxus cuspidata and mulberry tree, and mamufacturing method thereof Download PDFInfo
- Publication number
- KR100949482B1 KR100949482B1 KR1020090095563A KR20090095563A KR100949482B1 KR 100949482 B1 KR100949482 B1 KR 100949482B1 KR 1020090095563 A KR1020090095563 A KR 1020090095563A KR 20090095563 A KR20090095563 A KR 20090095563A KR 100949482 B1 KR100949482 B1 KR 100949482B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- mulberry
- hypertension
- people
- yew
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 120
- 235000008708 Morus alba Nutrition 0.000 title claims abstract description 90
- 240000000249 Morus alba Species 0.000 title claims abstract description 89
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims abstract description 13
- 244000162450 Taxus cuspidata Species 0.000 title claims abstract description 4
- 235000009065 Taxus cuspidata Nutrition 0.000 title claims abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 title abstract description 42
- 241001116500 Taxus Species 0.000 claims abstract description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 239000008213 purified water Substances 0.000 claims abstract description 9
- 239000007787 solid Substances 0.000 claims abstract description 9
- 238000010438 heat treatment Methods 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 238000001035 drying Methods 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 238000005406 washing Methods 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 50
- 241000018646 Pinus brutia Species 0.000 claims description 50
- 235000011613 Pinus brutia Nutrition 0.000 claims description 50
- 238000002360 preparation method Methods 0.000 claims description 31
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 24
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 12
- 235000013376 functional food Nutrition 0.000 claims description 9
- 230000036541 health Effects 0.000 claims description 8
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000005520 cutting process Methods 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 abstract description 5
- 230000000052 comparative effect Effects 0.000 description 32
- 239000008280 blood Substances 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 29
- 230000036772 blood pressure Effects 0.000 description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- 239000008103 glucose Substances 0.000 description 15
- 210000002216 heart Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 235000000346 sugar Nutrition 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 239000002775 capsule Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000008176 lyophilized powder Substances 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 230000035488 systolic blood pressure Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000035487 diastolic blood pressure Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Natural products C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010007749 Cataract diabetic Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 201000007025 diabetic cataract Diseases 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000011790 ferrous sulphate Substances 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000007602 hot air drying Methods 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- 229960000342 retinol acetate Drugs 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 235000019173 retinyl acetate Nutrition 0.000 description 2
- 239000011770 retinyl acetate Substances 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000218213 Morus <angiosperm> Species 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 241000219098 Parthenocissus Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241000872883 Tortella humilis Species 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940062310 avandia Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002892 effect on hypertension Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 주목과 뽕나무가 혼합된 추출물 또는 주목, 뽕나무 및 솔잎이 혼합된 추출물을 이용한 당뇨병 또는 고혈압의 치료제 및 이를 제조하는 방법에 관한 것이다. The present invention relates to a therapeutic agent for diabetes or hypertension using an extract mixed with yew and mulberry, or an extract mixed with yew, mulberry and pine needles and a method for producing the same.
현대인에게 있어서 식습관이 서구화됨에 따라 비만과 고지혈증, 고혈압 및 당뇨와 같은 생활 습관병의 발생율이 현저히 증가하고 있어 심각한 사회문제가 되고 있다. 특히, 한국인의 당뇨병 발생율은 최근 10년 사이에 급증하여 한국인의 사망요인 중 4위에 이르고 있는 실정이다. 당뇨병(Diabetes mellitus)은 인슐린의 분비량이 부족하거나 정상적인 기능이 이루어지지 않는 등의 대사질환의 일종으로, 혈중 포도당의 농도가 높아지는 고혈당을 특징으로 하며, 고혈당으로 인하여 여러 증상 및 징후를 일으키고 소변에서 포도당을 배출하게 된다. 당뇨병의 진단은 혈액검사로 진단한다. 증상이 없는 경우 8시간 이상 금식 후에 측정한 혈당이 126mg/dL 이상이거나, 경구 당부하 검사 2시간 후 혈당이 200mg/dL 이상인 경우를 당뇨병이라 한다. 물을 많이 마시거나 소변이 많아지고 체중이 감소하는 동시에 식사와 무관하게 측정한 혈당이 200mg/dL 이상일 때도 당뇨병으로 진단한다. As the eating habits are westernized in modern people, the incidence of lifestyle diseases such as obesity, hyperlipidemia, hypertension and diabetes has increased significantly, which is a serious social problem. In particular, the incidence of diabetes among Koreans has risen sharply in recent decades, making it the fourth largest cause of death among Koreans. Diabetes mellitus is a type of metabolic disease, such as insufficient insulin secretion or normal functioning. Diabetes mellitus is characterized by high blood sugar, which increases the concentration of glucose in the blood. Will be discharged. Diabetes is diagnosed by blood tests. If there is no symptom, the blood glucose measured after fasting for 8 hours or more is 126 mg / dL or more, or the blood sugar is 200 mg / dL or more 2 hours after the oral glucose load test. Diabetes is also diagnosed when people drink a lot of water, have more urine, lose weight, and have a blood sugar level of 200 mg / dL or more, regardless of their diet.
당뇨병은 전 세계적으로 중요한 성인병 중의 하나로서, 최근 우리나라에서도 급속한 경제 성장과 더불어 당뇨병 유병률이 7~8％에 달하며, 특히 합병증이 유발되기까지 전반적으로 수명이 길어짐에 따라 당뇨병 환자들은 합병증의 고통을 피할 수 없게 되었다. 일반적으로 당뇨병에 걸린 후 10~20년이 지나면 체내 거의 모든 기관이 손상을 받아 당뇨성 망막병증(diabetic retinopathy), 당뇨성 백내장(diabetic cataract), 당뇨성 신증(diabetic nephropathy), 당뇨성 신경병증(diabetic neuropathy) 등으로 나타난다. 만성 당뇨성 신증은 혈액 투석 치료 및 말기 신부전의 가장 중요한 원인이 되고 있으며, 당뇨성 백내장은 실명을 초래하고 결국엔 죽음에 이른다. 당뇨병의 치료는 일반적으로 식이요법이나 운동요법 및 약물요법 등을 병행하고 있는데, 이들 모두 지속적으로 정상 혈당을 유지시켜 당뇨합병증을 예방 또는 지연시키는 데 목표를 두고 있다. Diabetes is one of the most important adult diseases all over the world. In recent years, the prevalence of diabetes mellitus and the prevalence of diabetes has reached 7-8% in Korea, and the life expectancy of diabetic patients can be avoided due to their long life span. It became impossible. In general, almost 10 to 20 years after diabetes, almost all organs in the body are damaged, resulting in diabetic retinopathy, diabetic cataract, diabetic nephropathy, and diabetic neuropathy. diabetic neuropathy). Chronic diabetic nephropathy is the most important cause of hemodialysis treatment and end stage renal failure, and diabetic cataracts cause blindness and eventually death. Diabetes treatment is generally combined with diet, exercise therapy and drug therapy, all of which aim to prevent or delay diabetic complications by continuously maintaining normal blood sugar.
고혈압(Hypertension)은 정상 범위를 넘어서서 지속적으로 높은 혈압을 의미하는 것으로, 18세 이상의 성인에서 수축기 혈압이 140mmHg 이상이거나 확장기 혈압이 90mmHg 이상인 경우를 말한다. 수축기 혈압은 심장이 수축하면서 혈액을 내보낼 때 혈관에 가해지는 압력이고, 확장기 혈압은 심장이 확장(이완)하면서 혈액을 받아들일 때 혈관이 받는 압력이다.Hypertension refers to persistently high blood pressure beyond the normal range, with systolic blood pressure above 140 mmHg or diastolic blood pressure above 90 mmHg in adults 18 years of age and older. Systolic blood pressure is the pressure exerted on blood vessels as the heart contracts and releases blood, while diastolic blood pressure is the pressure the blood vessel receives when the heart receives blood as it expands (relaxes).
고혈압에는 최고 혈압만이 높은 경우와 최고 혈압과 최저 혈압 양쪽이 모두 높은 경우가 있는데, 보통 고혈압이라고 하는 것은 후자의 경우가 많고 최고 혈압만이 높은 경우는 심장에서 보내는 혈액량이 많아질 때와 대동맥의 탄력성이 감소되어 있을 때, 즉 어떤 종류의 심장판막증이거나 갑상선기능항진증, 대동맥경화, 대동맥류(大動脈瘤) 등인 경우이다. 최고 및 최저 혈압이 모두 높은 경우는 고혈압을 일으킨 병을 알 수 있는 것(2차성 또는 속발성)과 원인을 알 수 없는 것으로 유전적인 요소를 가진 것(1차성 또는 본태성)이 있다. 본태성 고혈압이 생기는 근본적인 이유는 명확하지 않지만, 심박출량(cardiac output; 심장에서 1분 동안 박출하는 혈액의 양)의 증가나 말초 혈관 저항의 증가로 인한 것으로 생각된다. 전체 고혈압 환자의 약 95%는 본태성 고혈압으로 비율적으로 압도적으로 많다. High blood pressure may be high only when the highest blood pressure is high, and both the highest blood pressure and the lowest blood pressure are high. Usually, high blood pressure is often the latter case, when only high blood pressure is high in the amount of blood from the heart and aorta When the elasticity is reduced, that is, some type of heart valve disease, hyperthyroidism, aortic hardening, aortic aneurysm, etc. When both the highest and lowest blood pressures are high, there is a known cause of hypertension (secondary or secondary) and an unknown cause of genetic factors (primary or essential). The underlying reason for the development of essential hypertension is not clear, but is thought to be due to an increase in cardiac output (a volume of blood ejected from the heart for 1 minute) or an increase in peripheral vascular resistance. About 95% of all patients with hypertension have an overwhelmingly high percentage of essential hypertension.
고혈압의 뇌신경증세로 가장 많은 것이 두통, 현기증, 이명(耳鳴), 흥분 등이며, 여기에 등이나 목의 결림 등이 따르는데, 이것들은 고혈압 초기에 보이는 증세로서 이러한 증세의 발작시에는 혈압이 일시적으로 높아진다. 그러나 점점 더 이러한 발작 증세가 짧은 간격으로 자주 일어나게 되고 나중에는 차차 발작이 없을 때도 계속 혈압이 높은 상태에서 원상태로 돌아가지 않게 된다. 이 시기가 되면 두통(특히 조기에), 현기증, 심박항진, 호흡곤란, 수면장애, 감정의 불안 등이 계속되고, 뇌의 동맥경화가 진행되면서 기억력 감퇴, 반신마비 증세가 나타나며, 안저 출혈로 인한 시력감퇴도 발생한다. 고혈압 증세를 보이는데도 치료를 받지 않은 채 몇 년이 지나게 되면 중요 장기(臟器)에 이상이 나타난다. 초기에 자각증세가 없던 사람도 이때쯤 되면 심박항진, 호흡곤란, 흉부압박감, 심장동통 등이 발작적으로 일어나고, 심장은 비대해지고 폐와 간에 울혈이 나타나며 하지(下肢)에 부기가 생 기거나 심한 호흡 곤란이 생긴다. 고혈압이 오래 계속되면 동맥경화도 조금씩 진행되고, 혈압은 더욱 높아지며 그에 따라서 동맥경화가 더 심해지는 악순환이 되풀이된다. 동맥경화는 전신, 특히 뇌, 심장, 신장에 일어나기 쉬우며, 신장에 일어나는 경우는 야간에는 빈뇨증이 아침에는 얼굴이 부석부석하고 발이 붓는 등의 증세가 발생한다. 고혈압과 관련된 위험 인자에는 고혈압의 가족력, 음주, 흡연, 고령, 운동 부족, 비만, 짜게 먹는 식습관, 스트레스 등의 환경적, 심리적 요인이 있다. The most common neurological symptoms of hypertension are headache, dizziness, tinnitus, and excitement, which are accompanied by stiffness in the back and neck, which are seen in the early stages of hypertension. Rises to. More and more, however, these seizures often occur at short intervals, and later on, even when there is no seizure, blood pressure continues to return to high levels. During this time, headaches (especially early), dizziness, palpitations, dyspnea, sleep disturbances, emotional anxiety continue, and as the arteries in the brain progress, memory loss and paraplegia develop, and due to fundus bleeding A decline in vision also occurs. After years of treatment without symptoms of hypertension, abnormal organs appear abnormal. At this time, even those who were not aware of the symptoms at this time, hypertension, shortness of breath, chest compressions, heart pain, seizures occur, the heart is enlarged, congestion of the lungs and liver, swelling in the lower extremities, severe breathing Difficulties arise. If hypertension continues for a long time, arteriosclerosis progresses little by little, blood pressure becomes higher, and thus the arteriosclerosis becomes a vicious cycle. Arteriosclerosis is easy to occur in the whole body, especially the brain, heart and kidneys, and when it occurs in the kidneys, anemia occurs at night, and the face is swollen in the morning and the feet are swollen. Risk factors associated with hypertension include environmental and psychological factors such as family history of high blood pressure, drinking, smoking, aging, lack of exercise, obesity, salty eating habits, and stress.
한편 본 발명에서 주목(朱木, Taxus cuspidata)은 겉씨식물 구과식물아강 주목목 주목과의 상록 교목으로 한국·일본·중국 동북부·시베리아 등에 분포하며 고산 지대에서 주로 서식한다. 일본산으로 원줄기가 곧게 서지 않고 밑에서 여러 개로 갈라지는 것은 눈주목(var.nana)이라고 하며, 잎이 보다 넓고 회색이 도는 것은 회솔나무(var.latifolia)라고 하며 울릉도와 북쪽에서 자란다. 원줄기가 비스듬히 자라면서 땅에 닿은 가지에서 뿌리가 내리는 것은 설악눈주목(T.caespitosa)이라고 하며 설악산 대청봉 근처에서 눈잣나무와 같이 자란다. 성장을 마친 주목은 높이 22m, 지름 2m에 달한다. 가지가 사방으로 퍼지고 큰 가지와 원대는 홍갈색이며 껍질이 얕게 띠 모양으로 벗겨진다. 잎은 줄 모양으로 나선상으로 달리지만 옆으로 벋은 가지에서는 깃처럼 2줄로 배열하며, 길이 1.5~2.5mm, 너비는 2~3mm로 표면은 짙은 녹색이고 뒷면에 황록색 줄이 있다. 잎맥은 양면으로 도드라지고 뒷면에는 가장자리와 중륵 사이에 연한 황색의 기공조선(氣孔條線:잎이 숨쉬는 부분으로 보통 잎 뒤에 흰 선으로 나타남)이 있다. 잎은 2~3년 만에 떨어진다. Meanwhile, in the present invention, the yew (朱 木, Taxus cuspidata ) is an evergreen tree of the attention tree of the creeper plant coniferous subfamily and is distributed in Korea, Japan, Northeast China, Siberia, etc. and mainly lives in the alpine region. It is a Japanese-made tree called var.nana, whose main stem does not stand straight and is divided into several branches from the bottom. The broader and grayer leaves are called var.latifolia, which grow on Ulleungdo and the north. The main stem grows at an angle and the roots from the branches that touch the ground are called T.caespitosa and grow like snow trees near Seoraksan Daecheongbong. After growing, the attention reaches 22m in height and 2m in diameter. Branches spread all over, large branches and fars are reddish brown, and their shells are shallow stripped. The leaves run in a spiral shape, but in the branch lined up side by side, they are arranged in two rows like feathers. The length is 1.5 ~ 2.5mm, the width is 2-3mm, the surface is dark green, and the green-yellow line is on the back. The leaf veins are raised on both sides, and on the back, there is a light yellow pore line between the edges and the middle of the leaves. The leaves fall in two to three years.
뽕나무(Mulberry tree 또는 Morus alba)는 쌍떡잎식물 쐐기풀목 뽕나무과 뽕 나무속에 속한 낙엽 교목 또는 관목을 총칭한다. 원산지는 온대·아열대 지방이다. 작은 가지는 회색빛을 띤 갈색 또는 회색빛을 띤 흰색이고 잔털이 있으나 점차 없어진다. 잎은 달걀 모양 원형 또는 긴 타원 모양 원형이며 3~5개로 갈라지고 길이 10cm로서, 가장자리에 둔한 톱니가 있으며 끝이 뾰족하다. 잎자루와 더불어 뒷면 맥 위에 잔털이 있다. Mulberry (Mulberry tree or Morus alba ) is a generic name for deciduous trees or shrubs belonging to the genus Nettle Mulberry and Mulberry. Origin is temperate and subtropical. Small branches are greyish brown or greyish white with fine hairs but gradually disappear. Leaves are oval-shaped or long oval-shaped, divided into 3 ~ 5 pieces, 10cm long, with dull sawtooth at the edge, and pointed at the end. Along with petioles, fine hairs on the back veins.
솔잎은 예로부터 오랫동안 이용된 식품 중의 하나로 주위에서 쉽게 구할 수 있는 재료이며 체질에 별로 구애받지 않고 누구나 섭취할 수 있는 식품으로 각종 질병의 치료 및 예방 효과가 우수하다. 솔잎에는 당질이 많이 들어 있으며, 필수 아미노산, 효소, 칼슘, 인, 철분, 엽록소 등 다양한 영양 성분이 들어있다. 솔잎은 각종 질병 치유와 예방에 놀라운 효과가 있는 것으로 알려지고 있다. 솔잎은 피를 맑게 하고 혈액순환을 잘되게 하여 말초신경을 확장시킨다. 이로 인해 호르몬의 분비를 높이며 중풍, 고혈압, 심근경색의 예방과 치유에 특효를 보이며 타박상, 신경통, 류머티즘 증세에도 잘 듣는다. 솔잎은 또한 요통이나 감기예방, 만성기관지염, 고혈압, 중풍, 신경통, 천식 등에 효과가 있고 수분대사를 잘 시켜주고 피부에 활력을 주며 소염, 소종 효과와 해독작용을 잘하여 여성들에게 불청객으로 찾아오는 월경불순, 냉대하, 자궁염, 자궁수탈증 등의 포괄적인 여성질환에 좋다. 또한 탄닌이 '멜라닌 색소'와 결합해 소변으로 배설되어 '멜라닌색소'가 침착되는 것을 막아 살결이 희어지고 매끄러워지는 효과를 가지며 피부에 탄력을 준다. 또한 신경을 안정시켜주는 효과가 있으며 혈당을 낮춰주는 성분인 글리코키닌도 포함하고 있어 당뇨병에도 도움을 주며 철분이 풍부해 빈혈에도 좋다고 알려져 있다.Pine needles are one of the foods that have been used for a long time and can be easily obtained from the surroundings and can be consumed by anyone, regardless of constitution, and are excellent in treating and preventing various diseases. Pine needles contain a lot of sugar and contain various nutrients such as essential amino acids, enzymes, calcium, phosphorus, iron, and chlorophyll. Pine needles are known to have an amazing effect on the healing and prevention of various diseases. Pine needles clear the blood and improve blood circulation, thereby expanding the peripheral nerves. This increases hormone secretion and is effective in preventing and healing strokes, hypertension, and myocardial infarction, and is well-recognized for bruises, neuralgia, and rheumatism. Pine needles are also effective in preventing back pain, colds, chronic bronchitis, hypertension, stroke, neuralgia, asthma, hydrating metabolism, revitalizing the skin, and anti-inflammatory, antiseptic effect and detoxification to menstruation that comes to women as an invisible visitor. It is good for comprehensive women's diseases such as impurity, cold, uterus, and uterus. In addition, tannins are combined with 'melanin pigment' to be excreted in the urine to prevent 'melanin pigment' from being deposited, which makes the skin whiter and smoother, and gives skin elasticity. In addition, it is effective in stabilizing nerves and contains glycokinin, a component that lowers blood sugar. It is known to be helpful for diabetes and is rich in iron, which is known to be good for anemia.
현재까지 당뇨병이나 고혈압 또는 이로 인한 합병증 등에 대한 수많은 연구가 진행되어 왔으나 아직도 완전한 치료법은 확립되어 있지 않은 실정에 있어 당뇨병이나 고혈압의 치료 또는 예방과 관련된 기능성 식품이나 의약품에 대한 지속적인 연구가 절실히 요구되고 있다. 이에 대해 본 발명자는 주목과 뽕나무 추출물을 이용하여 당뇨병과 고혈압을 치료할 수 있는 방법을 개발하였다. To date, numerous studies on diabetes, hypertension, or complications have been conducted, but there is still no complete treatment, and there is an urgent need for continuous research on functional foods and medicines related to the treatment or prevention of diabetes or hypertension. . In this regard, the present inventors have developed a method for treating diabetes and hypertension using yew and mulberry extract.
한국등록특허 제826672호에는 뽕나무와 버드나무를 주재료로 하며 일부 솔잎을 포함한 고혈압을 낮추기 위한 건강 음료에 대한 기술이 공지되어 있으며 한국공개특허 제2001-49156호에는 고혈압을 치료할 수 있는 솔잎 추출물에 대한 기술이 공지되어 있다. 한국등록특허 제529793호에는 당뇨병을 치료하기 위한 뽕나무 추출물에 대한 기술이 공지되어 있고 한국공개특허 제 2005-80501호에는 고혈압 및 당뇨병 환자를 위한 뽕잎 분말과 솔잎 분말이 포함된 건강보조식품에 대한 기술이 공지되어 있다. 그러나 상기 종래기술은 주목을 포함하지 않는 상태의 추출물 또는 혼합물 상태로서 본 발명의 주목과 뽕나무 추출물 또는 주목, 뽕나무 및 솔잎 추출물과 다르다. Korean Patent No. 826672 discloses a technique for health drinks for reducing hypertension, including pine needles and some pine needles as main ingredients, and Korean Patent Laid-Open No. 2001-49156 for pine needle extracts that can treat hypertension. Techniques are known. Korean Patent No. 529793 discloses a technology for mulberry extract for treating diabetes, and Korean Patent Publication No. 2005-80501 discloses a technology for health supplements containing mulberry leaf powder and pine needle powder for patients with hypertension and diabetes. This is known. However, the prior art is different from the yew and mulberry extract or yew, mulberry and pine needle extract of the present invention as an extract or a mixture state of not containing attention.
주목은 항암제인 택솔을 대량 증식시킬 수 있는 재료로 널리 알려져 있고 노화를 억제한다고 알려져 일부 화장료의 재료로 사용되고 있지만 현재까지 당뇨병이나 고혈압의 치료제로 사용된 사례는 없다. Attention is widely known as a material that can mass-produce taxol, an anticancer drug, and it is used as a material for some cosmetics because it is known to inhibit aging, but there have been no cases of treating diabetes or hypertension.
본 발명의 목적은 당뇨병과 고혈압을 치료하기 위한 주목과 뽕나무 추출물 또는 주목, 뽕나무 및 솔잎 추출물을 제공하는 데에 있다.An object of the present invention to provide a yew and mulberry extract or yew, mulberry and pine needle extract for treating diabetes and hypertension.
본 발명의 또 다른 목적은 주목과 뽕나무 추출물 또는 주목, 뽕나무 및 솔잎 추출물을 포함한 약학 제제와 건강기능식품을 제공하는 데에 있다. Still another object of the present invention is to provide a pharmaceutical preparation and health functional food including yeast and mulberry extract or yeast, mulberry and pine needle extract.
상기 기술적 과제를 달성하기 위해 주목과 뽕나무의 혼합 추출물을 제조하는 단계는, In order to achieve the above technical problem, the step of preparing a mixed extract of yew and mulberry,
(1공정) 주목과 뽕나무의 잎과 줄기를 세척 및 건조하는 단계;(Step 1) washing and drying leaves and stems of yew and mulberry;
(2공정) 상기 세척된 주목과 뽕나무를 사방 0.2~3cm로 세절하는 단계; (2 step) cutting the washed yeast and mulberry in 0.2 ~ 3cm everywhere;
(3공정) 상기 세절된 주목 20~60 중량부와 뽕나무 20~60 중량부를 혼합하는 단계; (3 step) mixing 20 to 60 parts by weight of the shredded yeast and 20 to 60 parts by weight of mulberry;
(4공정) 상기 주목과 뽕나무 혼합물에 중량대비 10~50배의 추출용매를 넣고 가열하는 단계; 및 (4 steps) 10 to 50 times the weight of the extraction solvent by weight in the mixture of yew and mulberry tree; And
(5공정) 상기 가열된 주목과 뽕나무 추출물을 여과한 여액을 수득하는 단계; (5 step) obtaining a filtrate obtained by filtering the heated yew and mulberry extract;
를 포함할 수 있다. It may include.
상기 3공정에서 주목과 뽕나무를 혼합하는 단계에서 솔잎을 세척하여 건조한 후 0.2~3cm로 세절된 솔잎을 전체 중량의 10~30 중량%로 추가할 수 있다. 솔잎을 추가한 추출물은 특히 고혈압에 효과가 있다. After washing the pine needles and drying the pine needles in the step of mixing the yew and mulberry in the third step may be added to 10 ~ 30% by weight of the pine needles finely sliced to 0.2 ~ 3cm. Extracts added pine needles are especially effective for high blood pressure.
상기 4공정에서 가열된 추출물은 상온으로 식힌 후 고형분을 제거하지 않는 상태에서 다시 동일 조건으로 재가열하는 과정을 수행할 수 있다. The extract heated in step 4 may be cooled to room temperature and then reheated under the same conditions without removing solids.
상기 4공정의 추출용매는 정제수, 알코올(메탄올, 에탄올, 이소프로판올, 부탄올), 유기용매 또는 이들의 혼합용매를 사용할 수 있으나 바람직하게는 정제수가 좋으며, 가열 단계는 70~125℃에서 1~10시간 동안 가열할 수 있다. 상기 가열은 직접적인 가열보다 추출물을 제조하는 통상의 중탕기를 이용하여 중탕 가열하는 것이 바람직하다. The extraction solvent of step 4 may be purified water, alcohol (methanol, ethanol, isopropanol, butanol), an organic solvent or a mixed solvent thereof, but preferably purified water, the heating step is 1 to 10 hours at 70 ~ 125 ℃ Can be heated during. The heating is preferably performed by heating the bath using a conventional water bath to prepare the extract rather than direct heating.
상기 5공정의 여과 과정은 가열 과정을 마친 추출물의 고형분을 가라앉혀 추출물을 여과할 때 통상적으로 사용하는 솜, 거름종이, 부직포, 여과지, 가는 체 등을 이용하여 고형분을 제거할 수 있다.The filtration process of the fifth step is to sink the solids of the extract after the heating process can remove the solids using a cotton, filter paper, non-woven fabric, filter paper, fine sieve, etc. commonly used to filter the extract.
상기 5공정의 주목과 뽕나무 추출물(솔잎 추출물 포함 가능)의 여과 여액은 별도의 가공없이 멸균 및 밀봉 포장하여 그대로 사용되거나 당뇨병과 고혈압의 치료를 위한 약학 제제나 건강기능식품에 포함되어 사용될 수 있다. 상기 주목과 뽕나무 추출물(솔잎 추출물 포함 가능)의 여과 여액은 성인 60kg 기준으로 100~150㎖씩 하루에 1~3회 복용되는 것이 바람직하다. Filtrate filtrate of the attention and mulberry extract (possibly pine needle extract) of the 5 step can be used as it is sterilized and sealed packaging without any additional processing or included in pharmaceutical preparations or health functional food for the treatment of diabetes and hypertension. The filtrate of the yew and mulberry extract (can include pine needles extract) is preferably taken 1 to 3 times a day 100 ~ 150ml by 60kg adult.
또는 상기 5공정의 주목과 뽕나무 추출물(솔잎 추출물 포함 가능)의 여과 여액은 동결건조, 열풍건조 또는 분무건조를 이용하여 분말화하여 약학 제제나 건강기능식품으로 제조하여 사용될 수 있다. Alternatively, the filtrate of the yeast and mulberry extract (possibly including pine needle extract) of the 5 step may be used as a pharmaceutical preparation or health functional food by powdering by lyophilization, hot air drying or spray drying.
당뇨병과 고혈압의 치료를 위해 약학적 조성물로서, 상기 주목과 뽕나무 추출물(솔잎 추출물 포함 가능)은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡 슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 상기 동결건조, 열풍건조 또는 분무건조 등을 이용하여 분말화 된 주목과 뽕나무 추출물(솔잎 추출물 포함 가능)을 함유하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토오즈, 덱스트로오즈, 수크로오즈, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화를 할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로스 또는 락토오스, 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마 크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. As a pharmaceutical composition for the treatment of diabetes and hypertension, the yeast and mulberry extract (which may include pine needle extract) are oral forms of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc. according to conventional methods, respectively. Formulations, external preparations, suppositories, and sterile injectable solutions can be formulated and used. Carriers, excipients and diluents that may be included in the composition containing the yeast and mulberry extract (including pine needle extract) powdered using lyophilization, hot air drying or spray drying may be lactose, dextrose, sucrose, etc. Oz, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, Propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid preparations may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin, or the like. Mix is prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
상기 활성성분의 투여량은 치료받을 대상의 연령, 성별, 체중과, 치료할 특정 질환 또는 병리 상태, 질환 또는 병리 상태의 심각도, 투여경로 및 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 투여량 결정은 당업자의 수준 내에 있으며, 일반적으로 투여량은 0.001㎎/㎏/일 내지 대략 2000㎎/㎏/일의 범위이다. 더 바람직한 투여량은 1㎎/㎏/일 내지 300㎎/㎏/일이다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다. The dosage of the active ingredient will vary depending on the age, sex and weight of the subject to be treated, the particular disease or pathology to be treated, the severity of the disease or pathology, the route of administration and the judgment of the prescriber. Dosage determination based on these factors is within the level of skill in the art and generally dosages range from 0.001 mg / kg / day to approximately 2000 mg / kg / day. More preferred dosage is 1 mg / kg / day to 300 mg / kg / day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
본 발명의 추출물은 쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 본 발명의 추출물은 독성 및 부작용은 거의 없어 장기간 복용시에도 안심하고 사용할 수 있는 약제이다. The extract of the present invention can be administered to mammals such as mice, livestock, humans, etc. by various routes. The extract of the present invention is a drug that can be used with confidence even for a long period of time because there is little toxicity and side effects.
또한, 본 발명의 주목과 뽕나무 추출물(솔잎 추출물 포함 가능)은 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 당뇨병과 고혈압 치료 개선을 위한 건강기능식품을 제공한다. 본 발명의 건강기능식품은 주목과 뽕나무 추출물(솔잎 추출물 포함 가능)의 여과 여액의 동결, 열풍 또는 분무 건조 분말, 정제, 캡슐제, 환제 또는 액제 등의 형태를 포함하며, 본 발명의 화합물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등이 있다. 상세하게는, 본 발명은 주목과 뽕나무 추출물(솔잎 추출물 포함 가능)을 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 당뇨병과 고혈압 예방 및 치료용 건강기능식품을 제공한다.In addition, the attention of the present invention and mulberry extract (can include pine needle extract) provides a dietary supplement for improving the treatment of diabetes and hypertension, including a food supplement acceptable food supplement. The health functional food of the present invention includes the form of frozen, hot air or spray-dried powder, tablets, capsules, pills or liquids of the filtrate of yew and mulberry extract (can include pine needle extract), and the compound of the present invention is added. Examples of foods that can be used include various foods, beverages, gums, teas, vitamin complexes, and health functional foods. In detail, the present invention provides a dietary supplement for diabetes and hypertension prevention and treatment comprising yeast mulberry extract (can include pine needle extract) food additives food acceptable.
주목은 항암제인 택솔을 대량 생산할 수 있는 주재료로 널리 알려져 있지만 아직까지는 당뇨병이나 고혈압에 사용된 적은 없으며 뽕나무 역시 뿌리를 주로 생약제제로 이용하지만 잎이나 가지가 갖는 약리학적 효과에 대해서는 알려진 것이 많지 않다. 이에 대해 본 발명자는 주목과 뽕나무 추출물 또는 주목, 뽕나무 및 솔잎 추출물이 당뇨병과 고혈압에 뛰어난 치료 효과를 갖는 것을 확인함으로 당뇨병 및 고혈압을 치료할 수 있는 조성물과 이의 제조 방법을 구현하였다. Attention is widely known as a main ingredient for mass production of anti-cancer drug Taxol, but it has not been used for diabetes or hypertension yet. Mulberry also uses root as a herbal medicine, but little is known about the pharmacological effects of leaves and branches. In this regard, the present inventors realized that the yeast and mulberry extract or yeast, mulberry and pine needles extract has an excellent therapeutic effect on diabetes and hypertension, and the composition and method for preparing the same can be treated.
이하, 본 발명의 바람직한 실시예를 상세히 설명하기로 한다. 그러나, 본 발명은 여기서 설명되는 실시예에 한정되지 않고 다른 형태로 구체화될 수도 있다. 오히려, 여기서 소개되는 실시예는 개시된 내용이 철저하고 완전해질 수 있도록 그리고 당업자에게 본 발명의 사상이 충분히 전달될 수 있도록 하기 위해 제공되는 것이다. Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms. Rather, the embodiments introduced herein are provided so that the disclosure may be made thorough and complete, and to fully convey the spirit of the invention to those skilled in the art.
<실시예 1 : 주목과 뽕나무를 혼합한 추출물 제조>Example 1 Preparation of Extracts Mixed with Yew and Mulberry
먼저 주목과 뽕나무의 잎과 줄기를 각각 4kg을 정제수에 세척한 후 건조한다. 세척된 주목과 뽕나무의 잎과 줄기는 사방 1cm로 세절한다. 세절된 주목과 뽕나무는 정제수 300kg에 넣고 120℃에서 4시간 동안 중탕 가열한다. 가열이 완료된 주목과 뽕나무 추출물은 다시 같은 조건에서 한 번 더 중탕 가열한 후 이후 고형분을 가라앉혀 여과한 여액을 수거한다. First, wash the leaves and stems of yew and mulberry 4kg each in purified water and then dry. The leaves and stems of the washed yeast and mulberry are cut in 1cm squares. The shredded yew and mulberry are put in purified water 300kg and heated in a bath at 120 ℃ for 4 hours. After heating, the yeast and mulberry extract is again heated in a bath under the same conditions, and then the solids are settled to collect the filtrate.
<실시예 2 : 주목, 뽕나무 및 솔잎을 혼합한 추출물 제조>Example 2 Preparation of Extracts Mixing Yew, Mulberry, and Pine Needles
상기 실시예 1의 제조방법과 동일하게 추출물을 제조하되 주목과 뽕나무를 혼합할 때 정제수에 세척하고 건조하여 1cm로 세절한 솔잎 2kg을 넣어준다. Prepare the extract in the same manner as in the preparation method of Example 1, but when mixing the yew and mulberry, put 2kg of pine needles, washed in purified water and dried to 1cm.
<비교예 1 : 주목 추출물의 제조>Comparative Example 1: Preparation of Yew Extract
상기 실시예 1의 제조방법과 동일하게 추출물을 제조하되 주목 8kg만을 이용하여 추출물을 제조하였다.The extract was prepared in the same manner as in Preparation Example 1, but the extract was prepared using only 8 kg of yeast.
<비교예 2 : 뽕나무 추출물의 제조>Comparative Example 2: Preparation of Mulberry Extract
상기 실시예 1의 제조방법과 동일하게 추출물을 제조하되 뽕나무 8kg만을 이용하여 추출물을 제조하였다.The extract was prepared in the same manner as in Preparation Example 1, but the extract was prepared using only 8 kg of mulberry.
<비교예 3 : 솔잎 추출물의 제조>Comparative Example 3: Preparation of Pine Needle Extract
상기 실시예 1의 제조방법과 동일하게 추출물을 제조하되 주목과 뽕나무 대신 솔잎 8kg만을 이용하여 추출물을 제조하였다.The extract was prepared in the same manner as in Preparation Example 1, but the extract was prepared using only 8 kg of pine needles instead of yew and mulberry.
<비교예 4 : 주목과 솔잎 추출물의 제조>Comparative Example 4: Preparation of Yew and Pine Needle Extract
상기 실시예 1의 제조방법과 동일하게 추출물을 제조하되 뽕나무 대신 솔잎 4kg을 이용하여 추출물을 제조하였다.The extract was prepared in the same manner as in Preparation Example 1, but the extract was prepared using 4 kg of pine needles instead of mulberry.
<비교예 5 : 솔잎과 뽕나무 추출물의 제조>Comparative Example 5: Preparation of Pine Needle and Mulberry Extract
상기 실시예 1의 제조방법과 동일하게 추출물을 제조하되 주목 대신 솔잎 4kg을 이용하여 추출물을 제조하였다.The extract was prepared in the same manner as in Preparation Example 1, but the extract was prepared using 4 kg of pine needles instead of attention.
<실험예 1 : 본 발명의 추출물의 급성 독성 실험>Experimental Example 1: Acute Toxicity Test of Extract of the Present Invention
실험하기 전 저녁부터 절식시킨 ICR 웅성생쥐(체중 24±1g)을 7마리씩을 한 군으로 하여 실시예 1 및 실시예 2의 추출물을 동결건조한 분말을 경구투여를 하였고, 행동의 이상 유무를 관찰하였다. 결과는 리치필드 제이 티 및 윌콕슨 에프의 방법에 따라 LD50 값을 산출하였고 다음 표 1에 나타내었다.ICR male mice (body weight 24 ± 1g) fasted from the evening before the experiment were grouped into seven groups, and the powders obtained by lyophilizing the extracts of Examples 1 and 2 were orally administered and observed for abnormal behavior. . The results were calculated LD 50 value according to the method of Richfield J. T. and Wilcoxon F. and are shown in Table 1 below.
상기 표 1에 나타난 바와 같이, 본 발명에 따른 실시예 1 및 실시예 2의 추출물이 경구 투여시 Rosiglitazone(항당뇨병성 약제)만큼 안정성이 우수한 것으로 나타났다. As shown in Table 1, the extracts of Examples 1 and 2 according to the present invention were found to be as stable as Rosiglitazone (antidiabetic drug) upon oral administration.
<실험예 2 : 동물 혈당 강하 효과 확인> Experimental Example 2: Confirmation of Animal Blood Sugar Drop Effect
상기 실시예 1에 의해 제조된 추출물의 혈당 강하 활성을 측정하기 위하여, 자발성 당뇨병 실험동물인 db/db 당뇨병 생쥐를 대상으로 혈당 강하 효과를 실험하였다. 먼저 동물에 경구 투여할 수 있도록 실시예 1 내지 2 및 비교예 1 내지 5의 추출물 각각을 동결건조하였다. In order to measure the hypoglycemic activity of the extract prepared in Example 1, the hypoglycemic effect was tested in db / db diabetic mice, which are spontaneous diabetic experimental animals. First, the extracts of Examples 1 to 2 and Comparative Examples 1 to 5 were lyophilized to be orally administered to the animals.
이후 실험군으로 당뇨병이 발현된 10주령의 웅성 db/db 생쥐를 사육 환경에 2주간 적응시킨 후 혈중 포도당 농도가 600mg/dL 내외의 당뇨병 생쥐를 실험대상 동물로 선정하였다. 실험군은 추출물을 투여하지 않는 대조군과 실시예 1 내지 2 및 비교예 1 내지 5의 시료 투여군으로 구분하고 각 군당 실험동물 수는 5마리씩으로 하였다. 시료의 조제 및 투여를 위해 상기 동결건조된 추출물들을 0.5% CMC(Carboxymethyl-cellulose)액을 사용하여 현탁액으로 조제하여 사용하였고, 각 추출물을 500mg/kg(체중)을 경구 투여하였다.Afterwards, 10-week-old male db / db mice with diabetes mellitus were adapted to a breeding environment for 2 weeks, and diabetic mice with a blood glucose level of about 600 mg / dL were selected as the test animals. The experimental group was divided into a control group not administering the extract and the sample administration groups of Examples 1 to 2 and Comparative Examples 1 to 5, and the number of experimental animals per group was 5. For the preparation and administration of the samples, the lyophilized extracts were prepared as a suspension using 0.5% CMC (Carboxymethyl-cellulose) solution, and each extract was orally administered at 500 mg / kg (body weight).
혈당의 측정은 비 공복상태에서 매일 오전 중에 꼬리에서 채혈하여 글루코스 옥시다아제법(Glucose oxidase method)으로 혈당을 측정하였으며, 그 결과를 다음 표 2에 나타내었다. Blood glucose was measured in the tail every morning in the non-fasted state, and blood glucose was measured by the glucose oxidase method. The results are shown in Table 2 below.
상기 표 2에 나타난 바와 같이, 본 발명에 따른 실시예 1 내지 2의 추출물을 처리한 군은 비교예 1 내지 5의 추출물과 대조군에 비해 우수한 혈당 강하 작용이 있음을 확인할 수 있었다. 실시예 1과 실시예 2의 추출물의 효과의 차이는 보이지 않았다.As shown in Table 2, the group treated with the extracts of Examples 1 to 2 according to the present invention was confirmed to have an excellent blood sugar lowering effect compared to the extracts of Comparative Examples 1 to 5 and the control group. No difference in the effects of the extracts of Example 1 and Example 2 was observed.
<실험예 3 : 동물 혈압 강하 확인>Experimental Example 3 Animal Blood Pressure Drop Confirmation
본 연구를 위하여, 6마리의 선천성 고혈압 쥐(SHR)를 사용하였다. 1주간의 적응기를 둔 후에, 실시예 1 내지 실시예 2 및 비교예 1 내지 비교예 5에서 제조된 추출물을 동결건조 한 후 각각 500㎎/㎏을 4주 동안 매일 쥐에게 먹였다. 대조군에는 추출물을 먹지 않는 군을 선택하였다. For this study, six congenital hypertensive rats (SHR) were used. After one week of adaptation, the extracts prepared in Examples 1 to 2 and Comparative Examples 1 to 5 were lyophilized, and then 500 mg / kg each were fed to mice daily for 4 weeks. The control group was selected not to eat the extract.
먼저 SHR을 무마취 상태로 실험에 사용하기 위하여 치우(Chiu) 등이 사용한 방법(Chuang C. Chiueh and Irwin J. Kopin;J. Physiol. 234(6), H690-H695, 1978)을 이용하여 다음과 같은 수술을 시행하였다. SHR에 체중 kg당 50mg 용량의 펜토바르비탈 나트륨(sodium pentobarbital)을 복강 내로 주사한 후 마취시킨 다음, 헤파린(heparin) 용액(500IU/ml in saline)을 채운 폴리에틸렌 도관(polyethylenecatheter; PE-50; Clay Adams)을 왼쪽 경동맥에 2cm 정도 삽입하고 피하를 통하게 하여 목 뒤쪽으로 뺐다. 이때 도관 및 수술기구는 70%의 알코올로 소독하여 수술에 사용하였으며 수술부위는 설파다이아진(sulfadiazine) 가루로 도포하였고, 도관 내의 혈액응고를 방지할 목적으로 헤파린(heparin) 용액을 1일 2회 0.5㎖씩 주입하였다. 혈압 및 심박동수의 관찰은 도관을 삽입하고, 24시간 경과 후 행하였다. 수축기 및 이완기 혈압은 경동맥에 삽입한 도관을 스타탐 압력변환기(Statham pressure transducer ; P23 ID)에 직접 연결하여 측정하였으며, 평균 동맥압은 다른 채널(channel)로 동시에 기록하였다. 압력 변환기(Pressure transducer)의 위치는 쥐 심장의 위치와 평행을 유지하였다. 심박동수는 동맥파의 카디오-타코그래프(cardio-tachograph; 7P44C)를 통하여 다른 채널에서 측정하였다. 혈압 및 심박동수를 측정하기 위하여 운반된 쥐는 안정 및 진정을 위하여 2시간 동안 방치한 후, 혈압 및 심박동수를 측정하였다. 실험 결과로 얻은 혈압 및 심박동수는 30초마다 5분간 읽은 10개의 값을 평균하여 구하였다. 혈압을 측정한 결과, 동일 심박수를 갖는 상태에서 수축기 혈압에 있어서 대조군 대비로 실시예 2의 추출물에서 뛰어난 수축기 혈압 강하 효과를 확인할 수 있었으며, 이완기 혈압 및 평균 혈압에서도 동일하게 관찰되었다(표 3 참조). 또한 실시예 1의 추출물은 약간의 효과가 있었으나 실시예 2의 추출물보다 효과가 높지는 않았고 비교예 1 내지 비교예 5에서는 별다른 효과를 나타내지 않았다. First, using the method used by Chiu et al. (Chuang C. Chiueh and Irwin J. Kopin; J. Physiol. 234 (6), H690-H695, 1978) to use SHR in experiments without anesthesia. The same operation was performed. SHR was injected intraperitoneally with 50 mg dose of sodium pentobarbital per kg body weight, followed by anesthesia, followed by polyethylene catheter (PE-50; Clay) filled with heparin solution (500 IU / ml in saline). Adams was inserted 2 cm into the left carotid artery and subcutaneously passed through the back of the neck. The catheter and surgical instruments were sterilized with 70% alcohol and used for surgery. The surgical site was applied with sulfadiazine powder, and heparin solution was applied twice a day to prevent blood coagulation in the catheter. 0.5 ml each was injected. Observation of blood pressure and heart rate was performed 24 hours after insertion of the catheter. Systolic and diastolic blood pressures were measured by connecting the catheter inserted into the carotid artery directly to a Statham pressure transducer (P23 ID), and the average arterial pressure was simultaneously recorded in different channels. The position of the pressure transducer was kept parallel to the position of the rat heart. Heart rate was measured in other channels via cardio-tachograph (7P44C) of arterial wave. Rats carried to measure blood pressure and heart rate were left for 2 hours for stability and sedation, and then blood pressure and heart rate were measured. The blood pressure and heart rate obtained as a result of the experiment were obtained by averaging 10 values read for 5 minutes every 30 seconds. As a result of measuring blood pressure, in the systolic blood pressure in the state having the same heart rate, it was confirmed that the excellent systolic blood pressure drop effect in the extract of Example 2 compared to the control group, the same was observed in the diastolic blood pressure and the average blood pressure (see Table 3). . In addition, the extract of Example 1 had a slight effect, but the effect was not higher than the extract of Example 2 and Comparative Examples 1 to 5 did not show a significant effect.
<실험예 4 : 임상 혈당 강하 확인> Experimental Example 4: Confirmation of Clinical Blood Sugar Drop
실시예 1 내지 실시예 2 및 비교예 1 내지 비교예 5의 추출물의 여과 여액을 각각 당뇨병 환자 15명에게 아침 저녁으로 하루에 두 번 120㎖씩 30일간 섭취하게 한 후 5일 간격으로 혈당을 측정하였다. 혈당의 측정은 8시간 이상 금식한 후에 자가 혈당 측정기를 사용하여 측정하였다. 대조군으로는 추출물을 섭취하지 않는 당뇨병 환자들을 비교하였다. 혈당 수치가 126mg/dL 이하의 혈당으로 내려간 것을 정상 혈당으로 회복하였다는 기준으로 하였다. 표 4는 각 혈당을 측정한 날짜에 각 추출물을 섭취한 당뇨병 환자들의 혈당이 15명 중에서 정상 혈당으로 회복된 인원 수를 나타내는 표이다. Filtrate filtrates of the extracts of Examples 1 to 2 and Comparative Examples 1 to 5 were each ingested by 120 ml twice daily for 30 days in the morning and evening for 30 days, and then blood glucose was measured at 5 day intervals. It was. Blood glucose was measured using a self glucose meter after fasting for at least 8 hours. As a control group, diabetic patients who did not consume the extract were compared. Blood glucose levels lowered to 126 mg / dL or less blood glucose were the basis for recovery to normal blood glucose. Table 4 is a table showing the number of people whose blood sugar recovered to normal blood glucose among 15 patients of diabetic patients who took each extract on the date of measuring each blood glucose.
표 4의 결과를 확인하면 실시예 1과 실시예 2의 추출물은 모두 당뇨병 환자의 혈당을 정상으로 회복시키는 효과가 있는 것으로 나타났다. 실시예 2에 추가된 솔잎 추출물은 혈당을 내리는 데에 별다른 영향은 미치지 않는 것처럼 보였으며 각각의 단일 추출물, 주목과 솔잎 추출물 및 뽕나무와 주목 추출물은 거의 효과가 없는 것으로 나타났다. Confirming the results of Table 4, the extract of Example 1 and Example 2 was found to have the effect of restoring the blood sugar of the diabetic patients to normal. The pine needle extract added in Example 2 did not seem to have any effect on lowering blood sugar, and each single extract, yew and pine needle extract and mulberry and yew extract showed little effect.
<실험예 5 : 임상 혈압 강하 확인>Experimental Example 5: Confirmation of Clinical Blood Pressure Drop
실시예 1 내지 실시예 2와 비교예 1 내지 비교예 5의 추출물의 여과 여액을 각각 고혈압 환자 15명에게 아침 저녁으로 하루에 두 번 120㎖씩 30일간 섭취하게 한 후 5일 간격으로 수동식 의료용 혈압계를 사용하여 혈압을 측정하였다. 혈압은 수축기 혈압이 140mmHg 이하 및 확장기 혈압이 90mmHg 이하의 혈압으로 내려간 경우를 정상으로 회복하였다는 기준으로 하였다. 표 5는 각 고혈압 환자의 혈압이 각 측정 날짜에서 15명 중에서 정상으로 회복된 인원 수를 나타내는 표이다.The filtrates of the extracts of Examples 1 to 2 and Comparative Examples 1 to 5 were each ingested by 120ml twice daily for 120 days twice a day in the morning and evening for 15 hypertension patients, and then manual medical sphygmomanometer at 5-day intervals. Blood pressure was measured using. The blood pressure was based on the fact that the systolic blood pressure was lowered to 140 mmHg or less and the diastolic blood pressure was lowered to 90 mmHg or less. Table 5 is a table showing the number of persons whose blood pressure of each hypertension patient returned to normal out of 15 at each measurement date.
표 5의 결과를 확인하면 실시예 2에서 주목과 뽕나무 추출물에 솔잎을 추가한 추출물이 고혈압을 정상 혈압으로 회복하는데 가장 효과가 좋았으며 주목과 뽕나무만을 이용한 추출물은 솔잎이 추가된 추출물보다는 효과가 덜하였다. 또한 각각의 단일 추출물과 주목과 솔잎 추출물 및 뽕나무와 솔잎 추출물은 거의 효과가 없었다. Checking the results of Table 5, the extract added pine needles to yeast and mulberry extract in Example 2 was the most effective in recovering high blood pressure to normal blood pressure, and extracts using only yew and mulberry trees were less effective than the extract added pine needles It was. Also, each single extract, yew and pine needle extract, and mulberry and pine needle extract had little effect.
본 발명을 이용하여 생성된 주목과 뽕나무 추출물 또는 주목, 뽕나무 및 솔잎 추출물은 의약품이나 식품에 첨가되어 당뇨병 또는 고혈압 치료제 등으로 제조되어 사용될 수 있다. Yew and mulberry extract or yeast, mulberry and pine needle extract produced using the present invention can be added to medicines or foods and prepared and used to treat diabetes or hypertension.
구체적인 예로서 본 발명은 주목과 뽕나무 추출물 또는 주목, 뽕나무 및 솔잎 추출물을 이용한 당뇨병과 고혈압을 치료하기 위한 약제와 기능성 식품의 제조방법을 제공한다. As a specific example, the present invention provides a pharmaceutical and functional food for treating diabetes and hypertension using yeast and mulberry extract or yeast, mulberry and pine needle extract.
<사용예 1: 약제의 제조예> <Use Example 1: Preparation of Pharmaceuticals>
1-1. 당뇨병 치료를 위한 산제의 제조 1-1. Preparation of Powders for Diabetes Treatment
실시예 1의 주목과 뽕나무 추출물의 동결건조 분말............. 300 mgLyophilized powder of yew and mulberry extract of Example 1 ...... 300 mg
유당 ...................................................... 100 mgLactose ... ..... 100 mg
탈크 ...................................................... 10 mgTalc ........................ ..... 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled in an airtight cloth to prepare a powder.
1-2. 고혈압 치료를 위한 산제의 제조 1-2. Preparation of Powders for the Treatment of Hypertension
실시예 2의 주목, 뽕나무 및 솔잎 추출물의 동결건조 분말....... 300 mgYew, lyophilized powder of mulberry and pine needle extract of Example 2 ....... 300 mg
유당 ....................................................... 100 mgLactose ... ...... 100 mg
탈크 ....................................................... 10 mgTalc ........................ 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled in an airtight cloth to prepare a powder.
1-3. 당뇨병 치료를 위한 정제의 제조 1-3. Preparation of Tablets for Diabetes Treatment
실시예 1의 주목과 뽕나무 추출물의 동결건조 분말.............. 300 mgLyophilized powder of yew and mulberry extract of Example 1 ........ 300 mg
옥수수전분 .................................................. 100 mgCorn Starch ... .. 100 mg
유당 ....................................................... 100 mgLactose ... ...... 100 mg
스테아린산 마그네슘 ........................................ 2 mgMagnesium Stearate ............................................... 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.
1-4. 고혈압 치료를 위한 정제의 제조 1-4. Preparation of Tablets for the Treatment of Hypertension
실시예 2의 주목, 뽕나무 및 솔잎 추출물의 동결건조 분말........ 300 mgYew, lyophilized powder of mulberry and pine needle extract of Example 2 ... 300 mg
옥수수전분 ................................................... 100 mgCorn Starch ... ... 100 mg
유당 ........................................................ 100 mgLactose ... ....... 100 mg
스테아린산 마그네슘 ......................................... 2 mgMagnesium Stearate ......................................... 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.
1-5. 당뇨병 치료를 위한 캅셀제의 제조 1-5. Preparation of capsules for the treatment of diabetes
실시예 1의 주목과 뽕나무 추출물의 동결건조 분말................ 300 mgLyophilized powder of the yew and mulberry extract of Example 1 ...... 300 mg
옥수수전분 ................................................... 100 mgCorn Starch ... ... 100 mg
유당 ......................................................... 100 mgLactose ... ........ 100 mg
스테아린산마그네슘 ........................................... 2 mgMagnesium Stearate ............................................... 2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.
1-6. 고혈압 치료를 위한 캅셀제의 제조 1-6. Preparation of capsules for the treatment of hypertension
실시예 2의 주목, 뽕나무 및 솔잎 추출물의 동결건조 분말.......... 300 mgYew, lyophilized powder of mulberry and pine needle extract of Example 2. 300 mg
옥수수전분 .................................................... 100 mgCorn Starch ... .... 100 mg
유당 .......................................................... 100 mgLactose ... ......... 100 mg
스테아린산마그네슘 ............................................ 2 mgMagnesium Stearate ......................................... 2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.
<사용예 2: 건강식품의 제조예> <Use Example 2: Production Example of Health Food>
2-1. 당뇨병 치료를 위한 건강식품의 제조2-1. Preparation of Health Foods for the Treatment of Diabetes
실시예 1의 주목과 뽕나무 추출물의 동결건조 분말................ 200 ㎎Freeze-dried powder of yew and mulberry extract of Example 1 ...... 200 mg
비타민 혼합물.................................................. 적량Vitamin Blend ... ..
비타민 A 아세테이트 .......................................... 70 ㎍Vitamin A Acetate ......................................... 70 μg
비타민 E ..................................................... 1.0 ㎎Vitamin E ... ..... 1.0 mg
비타민 B1 .................................................... 0.13 ㎎Vitamin B1 ... 0.13 mg
비타민 C ..................................................... 10 ㎎Vitamin C ... ..... 10 mg
비오틴 ........................................................ 10 ㎍Biotin ... ....... 10 ㎍
니코틴산아미드 ................................................ 1.7㎎Nicotinic Acid Amide ... 1.7mg
엽산........................................................... 50 ㎍Folic Acid ... 50 μg
판토텐산 칼슘 ................................................. 0.5 ㎎Calcium Pantothenate ......................................... 0.5 mg
황산제1철...................................................... 1.75 ㎎Ferrous Sulfate ............. ........ 1.75 mg
산화아연....................................................... 0.82 ㎎Zinc Oxide ... ....... 0.82 mg
탄산마그네슘 .................................................. 25.3 ㎎Magnesium Carbonate ... .. 25.3 mg
제1인산칼륨.................................................... 15 ㎎Potassium monophosphate ........................ ...... 15 mg
제2인산칼슘.................................................... 55 ㎎Dibasic calcium phosphate ..... ...... 55 mg
구연산칼륨..................................................... 90 ㎎Potassium Citrate ... ..... 90 mg
탄산칼슘 ...................................................... 100 ㎎Calcium Carbonate ... ...... 100 mg
염화마그네슘 .................................................. 24.8 ㎎Magnesium Chloride ... .. 24.8 mg
2-2. 고혈압 치료를 위한 건강식품의 제조2-2. Preparation of Health Foods for the Treatment of Hypertension
실시예 2의 주목, 뽕나무 및 솔잎 추출물의 동결건조 분말......... 200 ㎎Yew, Example of Freeze-dried Powder of Mulberry and Pine Needle Extract ......... 200 mg
비타민 혼합물.................................................. 적량Vitamin Blend ... ..
비타민 A 아세테이트 .......................................... 70 ㎍Vitamin A Acetate ......................................... 70 μg
비타민 E ..................................................... 1.0 ㎎Vitamin E ... ..... 1.0 mg
비타민 B1 .................................................... 0.13 ㎎Vitamin B1 ... 0.13 mg
비타민 C ..................................................... 10 ㎎Vitamin C ... ..... 10 mg
비오틴 ........................................................ 10 ㎍Biotin ... ....... 10 ㎍
니코틴산아미드 ............................................... 1.7㎎Nicotinamide ......................................................... 1.7 Mg
엽산........................................................... 50 ㎍Folic Acid ... 50 μg
판토텐산 칼슘 ................................................. 0.5 ㎎Calcium Pantothenate ......................................... 0.5 mg
황산제1철...................................................... 1.75 ㎎Ferrous Sulfate ............. ........ 1.75 mg
산화아연....................................................... 0.82 ㎎Zinc Oxide ... ....... 0.82 mg
탄산마그네슘 .................................................. 25.3 ㎎Magnesium Carbonate ... .. 25.3 mg
제1인산칼륨.................................................... 15 ㎎Potassium monophosphate ........................ ...... 15 mg
제2인산칼슘.................................................... 55 ㎎Dibasic calcium phosphate ..... ...... 55 mg
구연산칼륨..................................................... 90 ㎎Potassium Citrate ... ..... 90 mg
탄산칼슘 ...................................................... 100 ㎎Calcium Carbonate ... ...... 100 mg
염화마그네슘 .................................................. 24.8 ㎎Magnesium Chloride ... .. 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 제제예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다. 또한 수요계층이나, 수요국가, 사용 용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.The composition ratio of the above-mentioned vitamin and mineral mixtures is composed of relatively suitable ingredients suitable for health foods in the preferred formulation example, but the formulation ratio may be arbitrarily modified. The granules may be prepared and used for preparing a health food composition according to a conventional method. In addition, the compounding ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and use purpose.
도 1은 본 발명의 실시예 1에 따른 주목과 뽕나무 추출물을 제조하는 방법을 나타내는 순서도이다.1 is a flow chart showing a method for producing yew and mulberry extract according to Example 1 of the present invention.
도 2은 본 발명의 실시예 2에 따른 주목, 뽕나무 및 솔잎 추출물을 제조하는 방법을 나타내는 순서도이다.Figure 2 is a flow chart showing a method for producing yew, mulberry and pine needle extract according to Example 2 of the present invention.
Claims (8)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090095563A KR100949482B1 (en) | 2009-10-08 | 2009-10-08 | Phamaceutical composition of diabetes mellitus or hypertension using extract of taxus cuspidata and mulberry tree, and mamufacturing method thereof |
| PCT/KR2010/006829 WO2011043590A2 (en) | 2009-10-08 | 2010-10-06 | Pharmaceutical composition for treating diabetes or hypertension using taxus cuspidata and mulberry tree extracts, and method for preparing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090095563A KR100949482B1 (en) | 2009-10-08 | 2009-10-08 | Phamaceutical composition of diabetes mellitus or hypertension using extract of taxus cuspidata and mulberry tree, and mamufacturing method thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020100018372A Division KR100964603B1 (en) | 2010-03-02 | 2010-03-02 | Phamaceutical composition of diabetes mellitus using extract of taxus cuspidata and mulberry tree, and mamufacturing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR100949482B1 true KR100949482B1 (en) | 2010-03-24 |
Family
ID=42183782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020090095563A KR100949482B1 (en) | 2009-10-08 | 2009-10-08 | Phamaceutical composition of diabetes mellitus or hypertension using extract of taxus cuspidata and mulberry tree, and mamufacturing method thereof |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR100949482B1 (en) |
| WO (1) | WO2011043590A2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101310539B1 (en) * | 2013-01-18 | 2013-09-23 | 김석근 | Yew tree leaf contain a method of manufacturing a liquid extract, and the liquid extract |
| WO2016076447A1 (en) * | 2014-11-10 | 2016-05-19 | 주식회사 미라클바이오 | Pharmaceutical composition and antimicrobial composition for treating respiratory disease containing extract of morus alba |
| KR101736036B1 (en) * | 2015-06-15 | 2017-05-16 | 오동석 | A composition comprising extract of Taxus cuspidata, Morus alba L. and Momordica charantia L. for preventing or treating diabetes mellitus and mamufacturing method thereof |
| KR101791802B1 (en) * | 2016-12-29 | 2017-10-30 | 최동림 | A method for manufacturing health-promoting sphere and extract using herbal materials |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040077976A (en) * | 2001-09-07 | 2004-09-08 | 주식회사 엔바이오테크놀러지 | Extracts of pine having α- glucosidase inhibition activity and a extraction method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5800817A (en) * | 1996-03-11 | 1998-09-01 | Verge; Andre J. | Plant extracts and therapy for insulin deficiencies |
| KR100529793B1 (en) * | 1997-01-27 | 2005-11-23 | 링 지 | The extract of pine needle and the use thereof |
| US6551627B1 (en) * | 2001-05-03 | 2003-04-22 | Holomed Pharmaceuticals, Ltd. | Medicinal herbal compounds for the prevention and treatment of diabetes |
| KR20050031251A (en) * | 2003-09-29 | 2005-04-06 | 최진우 | Agent for treating and preventing a diabetes |
| KR20060120321A (en) * | 2005-05-19 | 2006-11-27 | 한상민 | Health care food composites for decreasing bloodglucose level |
-
2009
- 2009-10-08 KR KR1020090095563A patent/KR100949482B1/en not_active IP Right Cessation
-
2010
- 2010-10-06 WO PCT/KR2010/006829 patent/WO2011043590A2/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040077976A (en) * | 2001-09-07 | 2004-09-08 | 주식회사 엔바이오테크놀러지 | Extracts of pine having α- glucosidase inhibition activity and a extraction method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 생약 대사전(1990)* |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101310539B1 (en) * | 2013-01-18 | 2013-09-23 | 김석근 | Yew tree leaf contain a method of manufacturing a liquid extract, and the liquid extract |
| WO2016076447A1 (en) * | 2014-11-10 | 2016-05-19 | 주식회사 미라클바이오 | Pharmaceutical composition and antimicrobial composition for treating respiratory disease containing extract of morus alba |
| KR101736036B1 (en) * | 2015-06-15 | 2017-05-16 | 오동석 | A composition comprising extract of Taxus cuspidata, Morus alba L. and Momordica charantia L. for preventing or treating diabetes mellitus and mamufacturing method thereof |
| KR101791802B1 (en) * | 2016-12-29 | 2017-10-30 | 최동림 | A method for manufacturing health-promoting sphere and extract using herbal materials |
| WO2018124369A1 (en) * | 2016-12-29 | 2018-07-05 | 최동림 | Health enhancing pill and concentrate preparation method using morus alba and platycladus orientalis |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011043590A2 (en) | 2011-04-14 |
| WO2011043590A3 (en) | 2011-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104873808A (en) | Health tea capable of reducing high blood pressure, high blood sugar and high blood fat | |
| KR100949482B1 (en) | Phamaceutical composition of diabetes mellitus or hypertension using extract of taxus cuspidata and mulberry tree, and mamufacturing method thereof | |
| KR101189108B1 (en) | A composition containing dendropanax morbifera extract for improving sexual function | |
| KR100964603B1 (en) | Phamaceutical composition of diabetes mellitus using extract of taxus cuspidata and mulberry tree, and mamufacturing method thereof | |
| KR100976241B1 (en) | Extract of sedum sarmentosum for alcohol oxidation and relieves hangover | |
| CN103263054B (en) | Functional drink capable of reducing blood pressure | |
| CN104800608A (en) | Traditional Chinese herbal medicine composition with hypotensive effect and application thereof | |
| KR100601390B1 (en) | Anti-Obesity ingredients from medicinal plants and their composition | |
| KR20060130149A (en) | Composition comprising an aqueous extract of red vine leaves and a blood circulation-improving agent for the treatment of chronic venous insufficiences | |
| KR101765246B1 (en) | Composition for preventing and improving sex hormone-related disease | |
| KR101045025B1 (en) | Pharmaceutical composition for preventing or treatment of asthma | |
| CN101336965B (en) | Chinese prepared medicine for improving sugar tolerance and reducing blood sugar and preparation method thereof | |
| CN108260682A (en) | A kind of hypoglycemic, reducing blood lipid and the health protection tea of blood pressure lowering | |
| KR100967813B1 (en) | A composition comprising the extract of Raphani semen as an active ingredient showing anti-obesity and anti-hyperlipidemia activity | |
| CN107812115A (en) | A kind of Chinese medicine composition for treating diabetes | |
| US20040151794A1 (en) | Method of improvement of blood circulation | |
| CA2512147C (en) | Aqueous extract of red vine leave and use thereof for improving blood circulation | |
| CN101278940A (en) | Medicament composition for curing diabetic cardiovascular pathological changes and method of preparing the same | |
| KR101797993B1 (en) | Composition comprising crude drug of willow variant for treating, preventing or improvingcardiovascular disease | |
| KR100865900B1 (en) | Composition comprising an extract of herbal combination(occ-i) or the powder(occ-ii) thereof for preventing and treating diabetes mellitus | |
| KR100846521B1 (en) | Composition comprising an extract of herbal combination(oca-i) or the powder(oca-ii) thereof for preventing and treating diabetes mellitus | |
| KR102155113B1 (en) | Pharmaceutical composition and food composition for treating hypertension | |
| KR100761938B1 (en) | Pharmaceutical composition for preventing or treating impotence induced hyperlipidemia and/or hypertension | |
| KR20100102366A (en) | Composition of assitant healthful food | |
| KR101855820B1 (en) | Composition for improving hepatic function and enhancing stamina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| E902 | Notification of reason for refusal | ||
| A107 | Divisional application of patent | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| LAPS | Lapse due to unpaid annual fee |